Crossmark

Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation

Crossref DOI link: https://doi.org/10.1038/nchembio.2538

Published Online: 2017-12-18

Published Print: 2018-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Olson, Calla M

Jiang, Baishan

Erb, Michael A https://orcid.org/0000-0001-9993-3481
Liang, Yanke

Doctor, Zainab M

Zhang, Zinan https://orcid.org/0000-0003-3831-2272
Zhang, Tinghu

Kwiatkowski, Nicholas

Boukhali, Myriam

Green, Jennifer L

Haas, Wilhelm

Nomanbhoy, Tyzoon

Fischer, Eric S https://orcid.org/0000-0001-7337-6306
Young, Richard A https://orcid.org/0000-0001-8855-8647
Bradner, James E https://orcid.org/0000-0002-2718-4415
Winter, Georg E

Gray, Nathanael S https://orcid.org/0000-0001-5354-7403
License Information

Text and Data Mining valid from 2017-12-18
More Information

Article History

Received: 13 January 2017

Accepted: 9 November 2017

First Online: 18 December 2017

Competing interests

: N.S.G. is a Scientific Founder and member of the Scientific Advisory Board of C4 Therapeutics, Syros Pharmaceuticals and Petra Pharmaceuticals and is the inventor on intellectual property licensed to these entities. J.E.B. is a Scientific Founder of Syros Pharmaceuticals, SHAPE Pharmaceuticals, Acetylon Pharmaceuticals, Tensha Therapeutics (now Roche) and C4 Therapeutics and is the inventor on intellectual property licensed to these entities. J.E.B. is now an executive and shareholder in Novartis AG. R.A.Y. is a Scientific Founder of Syros Pharmaceuticals and Marauder Therapeutics.